Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H22BrNO3 |
| Molecular Weight | 379.277 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(Br)=C(OC)C=C1CCNCC2=CC=CC=C2O[11CH3]
InChI
InChIKey=SUXGNJVVBGJEFB-BJUDXGSMSA-N
InChI=1S/C18H22BrNO3/c1-21-16-7-5-4-6-14(16)12-20-9-8-13-10-18(23-3)15(19)11-17(13)22-2/h4-7,10-11,20H,8-9,12H2,1-3H3/i1-1
| Molecular Formula | C18H22BrNO3 |
| Molecular Weight | 379.277 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 18:19:15 GMT 2025
by
admin
on
Tue Apr 01 18:19:15 GMT 2025
|
| Record UNII |
NKZ2724LEK
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1404305-52-7
Created by
admin on Tue Apr 01 18:19:15 GMT 2025 , Edited by admin on Tue Apr 01 18:19:15 GMT 2025
|
PRIMARY | |||
|
50937472
Created by
admin on Tue Apr 01 18:19:15 GMT 2025 , Edited by admin on Tue Apr 01 18:19:15 GMT 2025
|
PRIMARY | |||
|
NKZ2724LEK
Created by
admin on Tue Apr 01 18:19:15 GMT 2025 , Edited by admin on Tue Apr 01 18:19:15 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET->RADIOLIGAND |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Official Title: Evaluation of (11C)Cimbi-36 as an Agonist PET Radioligand for Imaging of 5-HT2A Receptors
Purpose: The serotonin 2A (5-HT2A) receptor is the most abundant excitatory serotonin (5-HT, 5-hydroxytryptamine) receptor in the human brain, and multiple positron emission tomography (PET) studies have investigated the 5-HT2A receptors in the human brain using antagonist radioligands. However, the currently available antagonist PET radioligands bind the total pool of 5-HT2A receptor receptors whereas a 5-HT2A receptor agonist binds the high-affinity subgroup of the receptors which are also G-protein coupled, and thus hypothesized to be the functional relevant population of receptors. At the Center for Integrated Molecular Brain Imaging (CIMBI), a novel agonist PET radioligands for brain imaging of 5-HT2A receptors was recently validated in animals (Ettrup et al. 2011, EJNMMI). In the human brain, (11C)Cimbi-36 was validated as a selective 5-HT2A receptor agonist PET radioligand through a blocking study with the 5-HT2A receptor antagonist pharmaceutical ketanserin. In this validation study, the biodistribution and kinetic modelling of (11C)Cimbi-36 binding in the human brain was also validated. With these studies, investigators will test the most promising of these, (11C)Cimbi-36, in clinical trials, where it will provide a novel method for detecting dysfunction in the 5-HT system.
|
